A multitracer dopaminergic PET study of young-onset Parkinsonian patients with and without parkin gene mutations

Abstract

The impact of parkin gene mutations on nigrostriatal dopaminergic degeneration is not well established. The purpose of this study was to characterize by PET using 18F-fluoro-L-3,4-dihydroxyphenylalanine (18F-fluoro-L-DOPA), 11C-PE2I, and 11C- raclopride the pattern of dopaminergic lesions in young-onset Parkinson disease (YOPD) patients with or without mutations of the parkin gene and to correlate the clinical and neuropsychologic characteristics of these patients with PET results. Methods: A total of 35 YOPD patients were enrolled (16 with parkinmutation, 19without). The uptake constant (Ki) of 18F-fluoro-L-DOPA and the binding potential (BP) of 11C-PE2I (BPDAT) and of 11C-raclopride (BP D2) were calculated in the striatum. Comparisons were made between the 2 groups of YOPD and between controls and patients. For each radiotracer, parametric images were obtained, and statistical parametric mapping (SPM) analysis using a voxel-by-voxel statistical t test was performed. Correlations between the cognitive and motor status and PET results were analyzed. Results: In YOPD patients, 18F-fluoro-L-DOPA Ki values were reduced to 68%(caudate) and 40%(putamen) of normal values (P < 0.0001). This decrease was symmetric and comparable for nonparkin and parkin patients. No correlation was found between the Ki values and cognitive or motor status. 11C-PE2I BPDAT values in YOPD patients were decreased to 56% (caudate) and 41% (putamen) of normal values (P < 0.0001) and did not differ between the 2 YOPD populations. The mean 11C- raclopride BPD2 values were reduced to 72%(caudate) and 84% (putamen) of the normal values (P < 0.02) and did not differ between nonparkin and parkin patients. SPM analyses showed in patients an additional decrease of 11C-raclopride in the frontal cortex and a decrease of 18F-fluoro-L-DOPA and 11C-PE2I uptake in the substantia nigra bilaterally (P < 0.05, false-discovery rate-corrected). Conclusion: Carriers of parkin mutations are indistinguishable on PET markers of dopaminergic dysfunction from other YOPD patients with long disease duration. Copyright © 2009 by the Society of Nuclear Medicine, Inc.